Literature DB >> 4357604

Host responses to Epstein-Barr virus and cytomegalovirus infection in leprosy.

P S Papageorgiou, C F Sorokin, K Kouzoutzakoglou, R J Bonforte, P L Workman, P R Glade.   

Abstract

A study was undertaken in patients with leprosy to assess the contribution of cell-mediated immunity to the host response to Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infection. Sixteen of 72 patients (22%) with lepromatous leprosy, with impaired cellular immunity, had anti-EBV titers of 1,640 or higher. Only 4 of 49 patients (8%) with tuberculoid leprosy, with intact cell-mediated immunity, attained the level of 1:640. The anti-EBV antibody titers were significantly higher in patients with lepromatous leprosy (P approximately 0.025). No significant differences were found in the level of anti-CMV antibody titers in patients with the two types of leprosy. The presence of high anti-EBV antibody titers in lepromatous leprosy suggests that cell-mediated immunity is a significant factor in host response to EBV infection. Host immune responses should be taken into consideration when assignment of an etiological role to EBV is based upon seroepidemiological data.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4357604      PMCID: PMC422734          DOI: 10.1128/iai.7.4.620-624.1973

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells.

Authors:  L J Old; E A Boyse; H F Oettgen; E D Harven; G Geering; B Williamson; P Clifford
Journal:  Proc Natl Acad Sci U S A       Date:  1966-12       Impact factor: 11.205

2.  Sarcoidosis, another disease associated with serologic evidence for herpes-like virus infection.

Authors:  Y Hirshaut; P Glade; B D Vieira; E Ainbender; B Dvorak; L E Siltzbach
Journal:  N Engl J Med       Date:  1970-09-03       Impact factor: 91.245

3.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

4.  Raised antibody titres to E.B. virus in systemic lupus erythematosus.

Authors:  A S Evans; N F Rothfield; J C Niederman
Journal:  Lancet       Date:  1971-01-23       Impact factor: 79.321

5.  Association of herpes-like virus infection with infectious mononucleosis.

Authors:  Y Hirshaut; P Glade; H Moses; R Manaker; L Chessin
Journal:  Am J Med       Date:  1969-10       Impact factor: 4.965

6.  Significance of variations within the lepromatous group.

Authors:  D S Ridley; M F Waters
Journal:  Lepr Rev       Date:  1969-07       Impact factor: 0.537

7.  Biology of the mycobacterioses. Skin tests in leprosy.

Authors:  R S Guinto
Journal:  Ann N Y Acad Sci       Date:  1968-09-05       Impact factor: 5.691

8.  Lymphoproliferative potential in infectious diseases.

Authors:  P R Glade; I M Paltrowitz; K Hirschhorn
Journal:  Bull N Y Acad Med       Date:  1969-07

9.  Phytohaemagglutinin-induced lymphocyte transformation in leprosy.

Authors:  D S Nelson; M Nelson; J M Thurston; M F Waters; J M Pearson
Journal:  Clin Exp Immunol       Date:  1971-07       Impact factor: 4.330

Review 10.  Immunological phenomena in leprosy and related diseases.

Authors:  J L Turk; A D Bryceson
Journal:  Adv Immunol       Date:  1971       Impact factor: 3.543

View more
  4 in total

1.  Antibodies to Epstein-Barr virus in patients with cryptococcosis.

Authors:  P H Levine; R D Diamond; J I Reisher
Journal:  J Clin Microbiol       Date:  1975-04       Impact factor: 5.948

2.  Leukocyte migration inhibition in chorioretinitis.

Authors:  W L Henley; I H Leopold; S Okas
Journal:  Infect Immun       Date:  1974-05       Impact factor: 3.441

Review 3.  CD4+ Cytotoxic T Cells Involved in the Development of EBV-Associated Diseases.

Authors:  Manuel Ruiz-Pablos
Journal:  Pathogens       Date:  2022-07-25

Review 4.  Amplification of autoimmune disease by infection.

Authors:  David N Posnett; Dmitry Yarilin
Journal:  Arthritis Res Ther       Date:  2005-02-10       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.